Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAvMed Employer Plans Drug Formulary Coverage | Ope…
    Ask Trek AI about this page
    CurrentAvMedPolicy N/A

    AvMed Employer Plans 5-Tier Prescription Drug Formulary

    Customize your policy alerts

    Sign up for all AvMed policy alerts

    Know when AvMed releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines AvMed Employer Plans' prescription drug formulary structure, coverage rules, prior authorization and pharmacy use requirements for members and providers under the employer plan.

    Policy Summary
    PayerAvMed
    PolicyEmployer Plans 5-Tier Prescription Drug Formulary
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionPrescribers must obtain prior authorization for certain drugs and submit the completed drug authorization request form with supporting clinical documentation by fax to 1-305-671-0200.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5-tierformulary tier structure
    90mail-order days supply
    30 daysspecialty supply limit
    24h / 1-3dPA decision timeframes
    multiple

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    utilization controls examples

    Formulary Coverage Rules and Drug-Level Controls

    Formulary coverage rules and limits

    General coverage principles, supply limits, and common exclusions for AvMed Employer Plans pharmacy benefit.

    Formulary is reference only and does not guarantee coverage; coverage depends on member-specific benefit parameters and group benefit documents (contact Member Engagement for questions).
    AvMed may change formulary placement and coverage criteria throughout the year for reasons including new approvals, availability of generics, changes in clinical data, or safety concerns.
    Members must use in-network pharmacies and coverage is subject to plan benefit design; specialty drugs are limited to a 30-day supply and must be dispensed by a Plan Specialty Pharmacy unless manufacturer packaging dictates otherwise.
    Retail prescriptions: up to a 90-day supply (subject to plan terms); refills generally allowed after 75% of prior fill used. Mail-service: 31–90 day supply per prescription benefit (mail‑service copays apply).
    Brand additional charge applies when a member requests brand product over an approved generic; member cost-share may include non‑preferred brand copay plus brand additional charge.
    Non‑formulary requests, quantity‑limit exceptions, and Clinically Equivalent Drug (CED) requests require medical necessity documentation and follow the prior authorization process.
    Common exclusions: OTC products (unless specified), experimental or investigational use, non‑FDA/foreign medications, fertility drugs (unless specified), sexual dysfunction products (unless specified), vitamins/minerals, nutritional supplements/medical foods, cosmetic products, appetite suppressants (unless specified), most compounded prescriptions except pediatric preparations, and drugs covered under the medical benefit (see Group Medical and Hospital Service Contract).

    Drug tier and utilization control examples

    Selected literal formulary line examples showing drug tier and utilization control flags (PA, SP, QL, ST, CED, ACA) as shown in the excerpt.

    fluconazole oral tablet 100 mg, 200 mg — Tier 1; Requirements / Limits = QL (4 per 1 day).
    fluconazole oral tablet 150 mg — Tier 1; Requirements / Limits = QL (4 per 30 days).
    itraconazole oral capsule — Tier 2; Requirements / Limits = QL (4 per 1 day).
    ANCOBON — Tier 4; Requirements / Limits = PA.
    CRESEMBA ORAL CAPSULE 186 MG — Tier 4; Requirements / Limits = PA; QL (2 per 1 day).
    ORAVIG — Tier CED; Requirements / Limits = PA; 14 tablets per fill.

    Sample drug criteria nodes

    Sample drug-level criteria nodes drawn verbatim from the formulary lines (tier + explicit requirement flags and limits).

    VALCYTE ORAL RECON SOLN — Tier 5; Requirements / Limits = PA for age 9 and older; SP.
    VIREAD ORAL TABLET — Tier 5; Requirements / Limits = SP; QL (1 per 1 day).
    XOFLUZA ORAL TABLET 40 MG, 80 MG — Tier 4; Requirements / Limits = QL (1 per 183 days).
    DIFICID ORAL TABLET — Tier 4; Requirements / Limits = PA; 20 tablets per fill.
    TOBI PODHALER — Tier 5; Requirements / Limits = ST; SP; QL (224 per 28 days).
    SIRTURO ORAL TABLET 100 MG — Tier CED; Requirements / Limits = PA; LA; QL (188 per 168 days).

    sample coverage entries

    Literal coverage entries from the Adjunctive Agents section showing tier and any listed Requirements / Limits.

    abiraterone oral tablet 250 mg — Tier 5; Requirements / Limits = PA; SP; QL (4 per 1 day).
    VISTOGARD — Tier 5; Requirements / Limits = SP; QL (20 per 30 days).
    BLUJEPA — Tier 4; Requirements / Limits = PA; QL (20 per 30 days).
    fosfomycin tromethamine — Tier 2; Requirements / Limits = none listed in excerpt.
    leucovorin calcium oral tablet — Tier 1; Requirements / Limits = none listed in excerpt.

    Per-drug tier and administrative requirement examples

    Per-drug formulary placement and administrative controls recorded exactly as in the formulary lines (examples include specialty, PA, and QL by presentation).

    LORBRENA ORAL TABLET 100 MG — Tier 5; Requirements / Limits = PA; SP; QL (1 per 1 day).
    LUPRON DEPOT (various formulations) — Tier 5; Requirements / Limits = PA; SP; QL (1 per 28/63/84/126 days depending on formulation).
    MEKLINIST / MEKINIST formulations — Tier 5; Requirements / Limits = PA; SP; QL (various per day limits as listed).
    examples: Some agents may be Tier 1 or CED depending on formulation; e.g., megestrol oral suspension and megestrol oral tablet may have no PA or may be CED depending on formulation.

    Per-drug coverage with utilization management

    Coverage stance by drug/formulation with utilization management conditions where specified (PA, SP, LA, ST, QL).

    XTANDI (capsule/tablet) — Tier 5; Requirements / Limits = PA; SP; QL (capsule/tablet examples: 4 per 1 day; 2 per 1 day for 80 mg strength).
    ZEJULA ORAL TABLET — Tier 5; Requirements / Limits = PA; SP; LA; QL (1 per 1 day).
    ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG — Tier 5; Requirements / Limits = PA; SP; QL (1 per 63 days).
    APTIOM (200/400 mg) — Tier 4; Requirements / Limits = PA; QL (1 per 1 day).
    brivaracetam oral solution/tablet — solution: Tier 2; Requirements / Limits = PA; QL (12 per 1 day); tablet: Tier 2; Requirements / Limits = PA; QL (2 per 1 day).
    EPIDIOLEX — Tier 5; Requirements / Limits = PA; SP; LA.

    Per-drug tiering and constraints (excerpt)

    Per-drug tiering and constraints (excerpt) — formulary lines represent tier and listed Requirements / Limits per product.

    (Formulary lines in this segment list drug name, tier, and any explicit requirements/limits such as PA, SP, QL, ST or CED as applicable.)

    Formulary coverage entries with requirements

    Formulary entries that exemplify PA and QL controls and specialty designations.

    BELBUCA — Tier 4; Requirements / Limits = PA; QL (2 per 1 day).
    BRIXADI subcutaneous solution (various strengths) — Tier 5; Requirements / Limits = PA; SP; QL (strength‑specific per 28 days).
    buprenorphine (various forms) — Tier 1–2 depending on formulation; Requirements / Limits = PA for some formulations; QL examples include 12 per 1 day and 4 per 28 days as listed.

    Adjunctive agents coverage entries

    Adjunctive agents: sample entries showing tier, age‑based PA where applicable, and quantity limits.

    naloxone injection solution — Tier CED; Requirements / Limits = PA; QL (4 per 1 day).
    naproxen sodium oral tablet, er multiphase 24 hr — Tier CED; Requirements / Limits = PA; QL (2 per 1 day).
    ABILIFY ASIMTUFII INTRAMUSCULAR — Tier 3; Requirements / Limits = PA for age 17 and younger; QL specified (per 28 days).
    SUBOXONE sublingual films — Tier 4; Requirements / Limits = QL per day varying by strength (examples shown: 2/day, 12/day, 6/day, 3/day).
    VIVITROL — Tier 5; Requirements / Limits = SP.

    COVERAGE CRITERIA

    Additional Adjunctive Agents examples including age‑based PA and variable tiering by formulation.

    dextroamphetamine-amphetamine oral tablet — Tier 1; Requirements / Limits = PA for age 19 and older; QL (2 per 1 day).
    diazepam oral tablet — Tier 1; Requirements / Limits = none specified in these chunks.
    DRIZALMA SPRINKLE ORAL CAPSULE — Tier CED; Requirements / Limits = PA; QL (2 per 1 day).
    duloxetine (various DR/ER strengths) — Tier 1 or CED depending on strength; Requirements / Limits = PA and/or QL for some strengths (examples: QL (2 per 1 day); PA; QL (3 per 1 day)).
    DYANAVEL XR formulations — Tier 4; Requirements / Limits = PA; QL (8 per 1 day) or QL (1 per 1 day) depending on formulation.
    ERZOFRI intramuscular syringes (various mg/vol) — Tier 3; Requirements / Limits = PA for age 17 and younger; QL varying by strength (examples shown).

    Adjunctive agents coverage controls (selected examples)

    Selected adjunctive agent controls and high‑cost specialty product examples (PA, SP, LA, QL, age‑based PA).

    Quetiapine formulations — tiering varies (1–2/ CED depending on formulation); Requirements / Limits = PA for age 17 and younger; QL varies by formulation (examples: QL 3/day, QL 5/day, QL 2/day).
    Risperidone (various forms) — Tier 1–2; Requirements / Limits = PA for age 17 and younger; QL examples: 2 per day, 8 per day for solution, 2 per 28 days for microspheres.
    SPRAVATO (intranasal esketamine) — Tier 5; Requirements / Limits = PA; SP; QL (8–12 per 28 days depending on strength).
    MAVENCLAD (cladribine) tablet packs — Tier 5; Requirements / Limits = PA; regimen limits noted (2 tablets per day; 40 tablets in 720 days); SP; LA.
    XYREM / XYWAV / sodium oxybate — Tier 5; Requirements / Limits = PA; SP; LA; QL (18 per 1 day).

    Adjunctive agents coverage nodes

    Adjunctive agents entries showing step therapy, specialty designation, and example quantity limits.

    PLEGRIDY SUBCUTANEOUS SYRINGE — Tier 5; Requirements / Limits = ST; SP; QL (1 per 28 days) and alternate listing with QL (1 per 365 days) as shown.
    PONVORY — Tier 5; Requirements / Limits = PA; SP; QL (1 per 1 day); 14‑day starter pack: PA; SP; QL (28 per 365 days).
    VUMERITY — Tier 5; Requirements / Limits = PA; SP; QL (4 per 1 day).

    Antihypertensive therapy coverage nodes

    Antihypertensive therapy: common tiering patterns and examples of PA/QL/ST noted per product.

    amlodipine — Tier 1; Requirements / Limits = none listed.
    aliskiren — Tier 2; Requirements / Limits = PA; QL (1 per 1 day).
    ATACAND — Tier 4; Requirements / Limits = ST; QL (1 per 1 day).
    ENBUMYST — Tier CED; Requirements / Limits = PA; LA; QL (120 per 30 days).
    LOPRESOR ORAL SOLUTION — Tier CED; Requirements / Limits = PA; QL (20 per 1 day).
    diltiazem extended‑release forms — Tiering varies (1/2/CED depending on strength); Requirements / Limits = PA for some extended‑release forms.

    Coverage entries and utilization controls

    Coverage entries showing how tier and requirements/limits are recorded per cardiovascular product.

    NORVASC — Tier 4; Requirements / Limits = PA.
    ORENITRAM — Tiering appears as 1 and 5 for related kit/product entries; Requirements / Limits = PA; SP; QL (various per‑day and per‑year limits noted).
    UPTRAVI — Tier 5; Requirements / Limits = PA; SP; LA; QL (example: 2 per 1 day; dose pack QL 200 per 365 days).
    digoxin (various strengths) — Tiering ranges from 1 to CED depending on strength; some strengths are CED with PA.
    ELIQUIS suspension/sprinkle forms — Tier varies/CED; Requirements / Limits = PA; QL (examples: 112–448 per 28 days for suspension strengths).
    statins and lipid agents (e.g., atorvastatin, rosuvastatin, simvastatin) — Tier 1–4 depending on product; Requirements / Limits = ACA, PA, QL, ST noted for specific products.

    Formulary listing and utilization controls

    Cardiovascular and dermatology formulary examples highlighting tier assignments and utilization controls.

    rosuvastatin oral tablet 20 mg, 40 mg — Tier 1; Requirements / Limits = none listed.
    ROSZET — Tier CED; Requirements / Limits = PA; QL (1 per 1 day).
    TRYNGOLZA — Tier 5; Requirements / Limits = PA; SP; LA; QL (0.8 per 30 days).
    VASCEPA — Tier 4; Requirements / Limits = PA; QL (4 per 1 day).
    VYTORIN (various strengths) — Tier 4; Requirements / Limits = PA; QL (1 per 1 day).
    WELCHOL — Tier 4; Requirements / Limits = PA; QL (1 per 1 day).

    Per-product formulary placement and controls

    Product-level placement and example controls (tiers, PA, SP, ST, QL) for selected topical and biologic products.

    DUPIXENT PEN/SYRINGE (various strengths) — Tier 5; Requirements / Limits = PA; SP; QL (examples range from 2.28 per 28 days to 4 per 28 days depending on presentation).
    EUCRISA — Tier 4; Requirements / Limits = ST; QL (1 per 30 days).
    OPZELURA — Tier 5; Requirements / Limits = PA; SP; QL (60 per 30 days).
    CIBINQO — Tier 5; Requirements / Limits = PA; SP; QL (1 per 1 day).
    diclofenac sodium topical gel — Tier 1; Requirements / Limits = QL (100 per 365 days).
    tacrolimus topical — Tier 1; Requirements / Limits = none specified in this extract.

    Formulary Codes, Tiers and Quantity Limit Examples

    specialty_supply_limit
    Specialty supply limitSpecialty Medications are limited to a 30-day supply.
    Dispensing siteSpecialty medications must be dispensed by a participating specialty pharmacy when required.
    Manufacturer/package exceptionsSupply may be limited by manufacturer packaging; additional copayment may apply for amounts over 30 days.
    mail_service_supply_range
    Mail-service supply rangeMail-service prescription coverage includes a 31 to 90-day supply of most medications.
    Maximum via mailSome members can receive up to a 90-day supply of certain medications through mail service per their group benefits plan.

    Authorization, Submission and Documentation Requirements

    Prior Authorization

    Obtain prior authorization and submit required documentation

    The ordering prescriber must obtain prior authorization for certain prescription drugs. Submit the completed drug authorization request form and supporting clinical documentation by fax to 1-305-671-0200; pharmacy forms are available at https://www.avmed.org/prescriptions/ or https://www.avmed.org/forms/provider. Coverage decisions are made within 24 hours for urgent requests and within 1–3 business days for standard requests.

    Prior Authorization

    Allow member-initiated prior authorization requests

    Members may initiate a prior authorization by contacting AvMed Member Engagement (phone number on member ID card) or by logging into AvMed's prescriptions page and following the "Prescriptions" link; the member should provide the prescriber contact information and any pertinent clinical details for the request.

    Key Terms and Table Abbreviations

    Brand / Generic / Specialty definitions
    Brand MedicationA prescription medication manufactured and sold under a name or trademark or identified as Brand by AvMed's PBM.
    Generic MedicationA medication with the same active ingredient as a brand medication or identified as generic by AvMed's PBM.
    Specialty MedicationMedications classified as specialty by AvMed, generally for complex/ongoing conditions and limited to a 30-day supply.
    PA / ST / QL definitions
    Prior Authorization (PA)The process requiring the prescriber to obtain approval from AvMed before dispensing certain prescription drugs; approval is required prior to fill.
    Step Therapy (ST)A requirement to try specified first- or second-line medications before covering alternatives; prior authorization may be used when step therapy cannot be followed.
    Policy Summary
    PayerAvMed
    PolicyEmployer Plans 5-Tier Prescription Drug Formulary
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionPrescribers must obtain prior authorization for certain drugs and submit the completed drug authorization request form with supporting clinical documentation by fax to 1-305-671-0200.
    SourceLink
    On This Page
    Formulary Coverage Rules and Drug-Level ControlsFormulary Codes, Tiers and Quantity Limit ExamplesAuthorization, Submission and Documentation RequirementsKey Terms and Table Abbreviations
    PAXLOVID ORAL TABLETS, DOSE PACK 150 — Tier 3; Requirements / Limits = QL (40 per 365 days).
    PAXLOVID ORAL TABLETS, DOSE PACK 300 MG (150 MG X 2)-100 MG — Tier 3; Requirements / Limits = QL (60 per 365 days).
    BIKTARVY — Tier 5; Requirements / Limits = SP.
    EPCLUSA — Tier 5; Requirements / Limits = PA; SP; QL (1 per 1 day).
    BARACLUDE ORAL TABLET — Tier 5; Requirements / Limits = SP; QL (1 per 1 day).
    oseltamivir — Tier 1; Requirements / Limits = none listed.
    valacyclovir — Tier 1; Requirements / Limits = none listed.
    FINTEPLA — Tier 5; Requirements / Limits = PA; SP; LA; QL (12 per 1 day).
    gabapentin — tiering varies (1–2/CED depending on form); some ER forms require PA and QL as noted.
    LEVETIRACETAM — some forms Tier 1 or CED; certain forms require PA when marked CED.
    VALTOCO — Tier 4; Requirements / Limits = PA; QL (10 per 30 days).
    vigabatrin — Tier 5; Requirements / Limits = PA; SP; LA.
    XCOPRI (various packs/tablets) — Tier 4; Requirements / Limits = PA; QL (varies by pack/strength); titration pack: 1 unit/day; 1 box in 365 days.
    DUOPA — Tier 5; Requirements / Limits = PA; SP; QL (2800 per 28 days).
    INBRIJA (with inhalation device) — Tier 5; Requirements / Limits = PA; SP; QL (10 per 1 day).
    escitalopram products — Tiering varies (1–2 or CED); Requirements / Limits = QLs listed (examples include QL (1.5 per 1 day), QL (20 per 1 day)); some formulations marked CED with PA.
    INVEGA injectable products — Tier 3 or CED depending on product; Requirements / Limits = PA for age 17 and younger; QL specified per dosing interval (examples provided).
    LATUDA — Tier 4; Requirements / Limits = ST; PA for age 17 and younger; QL (1 per 1 day).
    methylphenidate formulations — Tier 1–2 or CED depending on strength/formulation; Requirements / Limits = PA for age 19 and older on many formulations; QL varies (examples: 3 per 1 day, 1 per 1 day).
    Multiple sclerosis injectables (e.g., COPAXONE, PLEGRIDY, GILENYA) — mostly Tier 5; Requirements / Limits = SP and QL with examples including COPAXONE (1 per day or 12 per 28 days); PLEGRIDY ST; SP; QL (1 per 28 or 365 days as listed).
    KESIMPTA PEN — Tier 5; Requirements / Limits = PA; SP; QL (0.4 per 28 days).
    TRINTELLIX, RELEXXII, REXULTI and other antidepressant/adjunctive agents — Tier 4; Requirements / Limits = PA and QL (commonly 1 per day for many listed agents).
    ORENITRAM (and associated titration kits) — multiple related entries (Tier 1/5 across kits); Requirements / Limits = PA; SP; QL (examples: 3 per 1 day; 168 per 365 days for kit entries).
    anticoagulants (e.g., rivaroxaban, apixaban, warfarin) — tiering varies (1–3) and some formulations (e.g., suspensions) have PA or QL as listed.
    CORLANOR oral solution/tablet — Tier 4; Requirements / Limits = QL (15 per 1 day solution; 2 per 1 day tablet).
    ENTRESTO / ENTRESTO SPRINKLE — Tier 4 (tablet) and CED (sprinkle); Requirements / Limits = QL (tablet 2 per 1 day; sprinkle PA; QL (8 per 1 day)).
    Dermatology biologics (selected): BIMZELX, COSENTYX, ILUMYA, DUPIXENT — commonly Tier 5 with Requirements / Limits = PA; SP; QL (examples: 1–4 per 28/42/63 days depending on presentation).
    Copay noteMail-service fills are subject to the listed mail-service copay per the member's prescription benefits even if quantity <90 days.
    Quantity Limits (examples)
    Example: 90-day style QLQL examples appear in various formats (e.g., QL (40 per 90 days) or per-year/period limits) as shown for multiple products.
    Example: per-30-day QLfluconazole oral tablet 150 mg — QL (4 per 30 days).
    Example: high per-fill QLTOBI PODHALER — QL (224 per 28 days).
    Quantity limits examples
    Common single-day QLsExamples include QL (1 per 1 day) and QL (6 per 1 day) for selected products.
    Large period QL examplesSIRTURO ORAL TABLET 100 MG — QL (188 per 168 days); DUOPA — QL (2800 per 28 days).
    Monthly exampleVALTOCO — QL (10 per 30 days).
    Quantity limits examples
    Per-30-day QL exampleVISTOGARD — QL (20 per 30 days).
    Per-day QL exampleabiraterone oral tablet 250 mg — QL (4 per 1 day).
    Per-28-day QL exampleglatiramer subcutaneous syringe 40 mg/ml — QL (12 per 28 days).
    Common QL units
    Per-day unit examplesExamples across the formulary include QL (2 per 1 day), QL (3 per 1 day), and QL (1 per 1 day).
    Per-28/63/135/365-day unitsCommon units used include per 28 days, per 63 days, per 135 days, and per 365 days per product listing.
    Fractional-unit examplesSome presentations list fractional QLs (e.g., QL (0.36 per 28 days) for certain extended dosing presentations).
    MAVENCLAD lifetime/pack limits
    MAVENCLAD per-day limitMAVENCLAD — 2 tablets per day (per pack presentation).
    MAVENCLAD long-term limitMAVENCLAD — 40 tablets in 720 days (regimen/pack-level lifetime limit).
    Associated requirementsMAVENCLAD entries include PA, SP, and LA flags in the formulary listings.
    ENBUMYST quantity limit
    ENBUMYST QLENBUMYST — QL (120 per 30 days).
    Associated flagsENBUMYST listed with PA and LA in addition to the quantity limit.
    Therapy areaENBUMYST appears in Antihypertensive/CV section as CED with PA/LA context in the formulary.
    PLEGRIDY syringe quantity limit
    PLEGRIDY syringe QLPLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML — QL (1 per 28 days).
    Alternate PLEGRIDY listingPLEGRIDY 63 MCG/0.5 ML – 94 MCG/0.5 ML — QL (1 per 365 days) for alternate presentation.
    FlagsPLEGRIDY entries include ST (step therapy) and SP (specialty) in addition to QL.
    VUMERITY quantity limit
    VUMERITY QLVUMERITY — QL (4 per 1 day).
    Associated utilization flagsVUMERITY is listed with PA and SP in addition to the QL.
    Class contextVUMERITY appears in the MS agents listing among other specialty products with SP/PA/QL flags.
    Sample quantity limits (reused)
    Examples: small per-day QLsExamples include QL (3 per 1 day) and QL (6 per 1 day) for stimulant/CNS products.
    Annual QL examplesExamples include QL (168 per 365 days) and QL (200 per 365 days) for titration kits and longer-term supplies.
    Other per-year examplesExamples such as QL (59 per 365 days) appear for certain specialty/topical products.
    Example quantity limit format (reused)
    QL notation conventionThe formulary consistently uses the format 'QL (n per X days)' across product listings.
    Daily and multi-day examplesExamples include QL (1 per 1 day), QL (2 per 1 day), and QL (0.5 per 63 days) depending on formulation.
    Biologic dosing examplesDUPIXENT — QL (2.28 per 28 days) up to QL (4 per 28 days) depending on presentation.
    Quantity limits examples
    Per-28-day fractional QL examplesDUPIXENT pen/syringe — QL (2.28 per 28 days) and QL (4 per 28 days) depending on presentation.
    Per-28/30-day QLsDUPIXENT and other biologics frequently use per-28-day units; OPZELURA — QL (60 per 30 days).
    Per-year QL examplesSome products show QL (30 per 365 days) or QL (60 per 365 days) for longer-period limits.
    Documentation Required

    Provide medical necessity documentation for exceptions, non‑formulary, and CED requests

    Requests for quantity limit exceptions, non‑formulary medications, or Clinically Equivalent Drugs (CED) require medical necessity documentation from the prescriber (e.g., medical records, prescription history, statement of medical necessity, contraindications, or therapeutic failure documentation) and must follow the prior authorization process.

    Prior Authorization

    PA required before fill for listed drugs

    Prior Authorization (PA) is required for certain drugs; approval must be obtained before dispensing or the drug may not be covered by the plan.

    Step Therapy

    Comply with step therapy requirements before coverage

    Step Therapy (ST) may require trying specified drugs first before covering alternative therapies; if step therapy cannot be followed, prior authorization is used to request coverage.

    Note

    Check utilization management flags on formulary entries

    Many formulary entries display utilization flags (PA, SP, ST, QL, ACA, LA, CED) indicating administrative controls; review product flags on the formulary line to determine prescriber actions required.

    Prior Authorization

    Verify PA, specialty, and quantity-limit requirements per product

    Formulary lines commonly list Prior Authorization (PA), Specialty designation (SP), and Quantity Limits (QL) — verify PA and any SP/QL requirements for the specific product before prescribing.

    Denial Risk

    Recognize PA, QL, and CED flags that can trigger denials

    Several agents are specifically marked with PA, QL, and CED indicators; failure to follow these requirements may result in denial of coverage.

    Prior Authorization

    Follow PA, SP, and QL rules for adjunctive agents

    Many adjunctive agents require Prior Authorization, Specialty Pharmacy processing, and Quantity Limits (and some Limited Availability); follow the formulary-listed PA/SP/QL rules when prescribing these agents.

    Prior Authorization

    Confirm age-based PA restrictions on formulary lines

    Some products include age‑based prior authorization requirements (for example, PA for age 9 and older on specific agents); confirm age‑based PA criteria on the formulary line before prescribing for pediatric or young adult patients.

    Prior Authorization

    Verify product-level PA/ST/other restrictions before prescribing

    Numerous products in the formulary require PA, ST, or other utilization controls (examples include XROMI, XTANDI, ZEJULA); verify the specific authorization requirement for the product being prescribed.

    Billing Rule

    Adhere to posted quantity limits or request QL exception

    Quantity limits are commonly applied (e.g., brivaracetam oral solution QL = 12 per 1 day); check the formulary line for the exact QL and request a quantity‑limit exception via prior authorization if the prescription exceeds the limit.

    Prior Authorization

    Confirm PA and specialty/limited‑access status for high‑cost agents

    Many drugs require PA and may also be designated specialty (SP) or limited access (LA); confirm PA/SP/LA status for high‑cost or specialty products before initiating therapy.

    Documentation Required

    Review PA and QL for migraine and adjunctive therapies

    Migraine and adjunctive therapies often include PA and QL controls; review formulary entries for those products to determine documentation and quantity requirements.

    Prior Authorization

    Verify PA/SP/QL for listed products

    Many listed products require prior authorization; some also have specialty pharmacy requirements and quantity limits — verify product‑specific PA/SP/QL before prescribing.

    Billing Rule

    Arrange specialty pharmacy processing and observe per‑28‑day QLs

    Some specialty products are designated SP and have per‑28‑day QLs (for example, BRIXADI and SUBLOCADE entries show SP with 28‑day limits); arrange specialty pharmacy fulfillment and observe per‑28‑day QLs where listed.

    Documentation Required

    Include specific PA and QL details in authorization requests

    Multiple formulary entries list PA and specific QLs (examples include naloxone injection PA; QL 4 per 1 day and other PA+QL combinations); include exact QL and PA details from the formulary when submitting authorization requests.

    Step Therapy

    Follow combined ST/SP/QL/PA rules for adjunctive agents

    Adjunctive agents in the table include many PA, SP, and QL examples (e.g., PLEGRIDY ST; SP; QL 1 per 28 days; PONVORY PA; SP; QL 1 per day); follow the formulary-specified mix of ST/SP/QL/PA for these agents.

    Prior Authorization

    Confirm age criteria for PA on applicable products

    Age-based PA restrictions are frequent (e.g., PA for age 17 and younger for multiple injectable antipsychotics; PA for age 19 and older for some stimulants); confirm age criteria on the formulary prior to prescribing.

    Billing Rule

    Confirm QL time units (per day/28/365) when prescribing

    Quantity limits are routinely specified per day, per 28 days, or per 365 days alongside PA; confirm the exact QL unit (per day/28/365) on the formulary and request exception if clinically indicated.

    Prior Authorization

    Verify age‑based PA and QL for quetiapine formulations

    Quetiapine formulations require PA for members age 17 and younger and have formulation‑specific QLs; verify age‑based PA and the applicable QL for the chosen quetiapine formulation.

    Documentation Required

    Check formulation‑specific PA and QL for risperidone

    Risperidone formulations require PA for members age 17 and younger and list QLs by formulation (e.g., microspheres QL 2 per 28 days, oral solution QL 8 per day); check the exact formulation line for the correct QL before prescribing.

    Prior Authorization

    Ensure PA and specialty routing for MS agents and observe QLs

    Multiple sclerosis agents frequently require PA, SP, and sometimes Step Therapy (ST) with QLs (examples include COPAXONE, GILENYA, MAVENCLAD); ensure PA and SP routing and that QL limits are observed.

    Prior Authorization

    Obtain PA and route to specialty pharmacy for specialty agents

    Specialty nasal or other high‑cost specialty agents (e.g., SPRAVATO) require PA and are designated SP with specific per‑28‑day QLs; obtain PA and coordinate specialty pharmacy fulfillment per the formulary.

    Prior Authorization

    KESIMPTA: PA, SP designation, and QL 0.4 per 28 days

    KESIMPTA PEN requires Prior Authorization, is designated Specialty (SP), and has a QL of 0.4 per 28 days; include these exact requirements in the authorization submission and arrange SP fulfillment.

    Prior Authorization

    Follow product‑specific combos of ST/PA/SP/QL (e.g., PLEGRIDY, PONVORY)

    Formulary examples show combined requirements such as ST; SP; QL (1 per 28 days) for PLEGRIDY and PA; SP; QL for PONVORY — confirm and follow the exact combination of ST/PA/SP/QL when prescribing these products.

    Documentation Required

    Cite exact PA/SP/QL values (e.g., VUMERITY, TASCENSO) in requests

    Examples across the formulary list PA and QL details for products (e.g., VUMERITY: PA; SP; QL 4 per 1 day; TASCENSO ODT: PA; SP; QL 1 per 1 day); ensure authorization requests cite the precise PA/SP/QL values shown.

    Prior Authorization

    Verify PA/ST/QL for antihypertensive products

    Many antihypertensives show utilization controls including PA, ST, and QLs (for example, ENBUMYST listed with PA; LA; QL 120 per 30 days); verify antihypertensive product requirements before prescribing.

    Note

    Review formulary line for utilization controls before prescribing

    Most listed drugs are subject to utilization controls such as PA, QL, ST, and SP; review the formulary line to determine required prescriber actions and documentation prior to dispensing.

    Denial Risk

    Check utilization flags to avoid denials

    The formulary uses flags (PA, QL, SP, LA, ST) extensively; check these flags per product to avoid coverage denials or claim rejections.

    Prior Authorization

    Obtain PA and SP for dermatology biologics and follow QLs

    Dermatology biologics commonly require Prior Authorization and many also require Specialty (SP) and specific Quantity Limits (per 28/42/63 days); obtain PA and arrange SP fulfillment as required for biologics.

    Prior Authorization

    Confirm authorization pathway (PA/SP/ST/QL) for each agent

    Many agents require prior authorization; some require site‑of‑care prior authorization or specialty pharmacy routing, step therapy, and quantity limits — confirm the exact authorization pathway for each agent before prescribing.

    Documentation Required

    Follow product‑level controls (e.g., DUPIXENT, EUCRISA, OPZELURA)

    Product‑level examples: DUPIXENT requires PA, SP, and QL; EUCRISA requires ST; OPZELURA requires PA, SP, and QL — follow these specified controls when submitting authorization requests.

    Quantity Limit (QL)A maximum quantity per prescription and/or time period for one copay or coinsurance; quantity limits are set per FDA labeling and clinical guidelines.
    CED / SP / abbreviations
    CED (Clinically Equivalent Drug)Clinically Equivalent Drugs may not be covered if a clinically equivalent formulary drug is available; CED entries require clinical review.
    SP (Specialty)Specialty Drug designation used for medications that require dispensing through a specialty pharmacy and often limited to 30-day supply.
    Abbreviation key locationMeanings for symbols and abbreviations (PA, SP, QL, ST, CED, LA, ACA) are defined at the beginning of the full formulary table.
    Formulary short-code definitions
    PA (short code)PA = Prior Authorization (approval required before fill).
    QL (short code)QL = Quantity Limit (limits the amount covered over a time period).
    SP (short code)SP = Specialty (specialty pharmacy designation/requirement).
    Mail-service prescriptions
    Mail-service prescriptionsMail-service prescriptions: eligible members can receive up to a 90-day supply (mail-service coverage generally 31–90 days).
    Retail vs mailRetail coverage includes up to a 90-day supply for the listed copay; some plans allow 90-day retail or mail for reduced cost.
    Copay applicationMail-service fills are charged the listed mail-service copay per the member's prescription benefits even if quantity <90 days.
    Formulary requirement flags
    Formulary requirement flagsCommon flags used in the formulary: PA = prior authorization; SP = specialty; QL = quantity limit; ST = step therapy; CED = clinically equivalent drug; LA = limited availability; ACA = ACA-covered drugs.
    Where definedThese abbreviations and symbols are defined at the start of the full formulary table (legend at table beginning).
    Usage across tablePA, SP, QL, ST, CED flags appear throughout product listings to indicate utilization controls and requirements.
    Table abbreviations (key)
    Table abbreviationsPA = Prior Authorization; QL = Quantity Limit; SP = Specialty; LA = Limited Access; CED = Clinically Equivalent/Clinical Edit.
    Legend noteThe symbol/abbreviation key is referenced at the beginning of the formulary table for full explanations.
    Clinical intentAbbreviations indicate administrative controls (e.g., PA for authorization, QL for quantity constraints, ST for step therapy).